Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
NCT07400588 on ClinicalTrials.gov · last registry update 2026-04-27
Closed to new participants; the 58 already enrolled are still being followed. The sponsor logged completion for September 2026. Primary outcome, as filed: Incidence, severity and relationship of AEs/SAEs. aleniglipron is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P2
- Drug
- aleniglipron
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Sponsor type
- Industry
- Enrollment
- 58
- Started
- 2025-12-01
- Primary completion
- 2026-09 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-08-21 | First seen in registry | Registered as ACTIVE_NOT_RECRUITING, P2 |
Primary outcome
Incidence, severity and relationship of AEs/SAEs
Conditions studied
Obese · Obesity · Obesity Type 2 Diabetes Mellitus · Weight Loss
Every field above is taken directly from the registry record. See all detected changes across the class, or the aleniglipron page for this molecule’s full trial and approval history.